MUC1 and ovarian carcinoma: Data from the NHS showed that women with higher anti-MUC1 antibodies subsequently had a lower risk for ovarian cancer developing before age 65 (110), and data from the EPIC cohort showed that elevated levels of anti-MUC1 antibodies may lower the risk for serous ovarian cancers arising within 3 years of the blood draw (111).